Rifaximin is a non-absorbable, semisynthetic antibiotic that acts as an inhibitor of bacterial RNA synthesis, with a broad spectrum of antibacterial activity. Due to its poor absorption, rifaximin has an increased exposure to the intestine, thus it is suitable for the treatment of many gastrointestinal (GI) diseases. In irritable bowel syndrome (IBS) pathogenesis, gut microbiota impairment may play a major role. The possibility of modulating intestinal bacteria using antibiotics, in particular, rifaximin, has been demonstrated to improve IBS symptoms in non-constipation subtypes of IBS.
Laterza, L., Ianiro, G., Scoleri, I., Landi, R., Scaldaferri, F., Gaetani, E., Campanale, M., Gasbarrini, A., Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome, <<EXPERT OPINION ON PHARMACOTHERAPY>>, 2015; 16 (4): 607-615. [doi:10.1517/14656566.2015.1007951] [http://hdl.handle.net/10807/68311]
Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome
Laterza, Lucrezia;Ianiro, Gianluca;Scoleri, Iolanda;Landi, Rosario;Scaldaferri, Franco;Gaetani, Eleonora;Campanale, Mariachiara;Gasbarrini, Antonio
2015
Abstract
Rifaximin is a non-absorbable, semisynthetic antibiotic that acts as an inhibitor of bacterial RNA synthesis, with a broad spectrum of antibacterial activity. Due to its poor absorption, rifaximin has an increased exposure to the intestine, thus it is suitable for the treatment of many gastrointestinal (GI) diseases. In irritable bowel syndrome (IBS) pathogenesis, gut microbiota impairment may play a major role. The possibility of modulating intestinal bacteria using antibiotics, in particular, rifaximin, has been demonstrated to improve IBS symptoms in non-constipation subtypes of IBS.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
